459-28-9Relevant academic research and scientific papers
Iron-Catalyzed Intramolecular C—H Amidation of N-Benzoyloxyureas
Zhong, Dayou,Wu, Lin-Yang,Wang, Xing-Zhen,Liu, Wen-Bo
, p. 855 - 858 (2021/02/16)
A redox-neutral Fe-catalyzed intramolecular C—H amidation of N-benzoyloxyureas is described. This methodology employs a simple iron complex in situ generated from Fe(OTf)2 and bipyridine as the catalyst and N-benzoyloxyureas as the nitrene prec
Palladium-Catalyzed C(sp2)-H Olefination of Free Primary and Secondary 2-Phenylethylamines: Access to Tetrahydroisoquinolines
Fan, Shuai,Ding, Yongzheng,Chen, Xiaoxi,Gao, Yuzhen,Fu, Lei,Li, Shangda,Li, Gang
, p. 13003 - 13012 (2019/10/11)
A rapid construction of THIQs by a Pd(II)-catalyzed C(sp2)-H olefination of free primary and secondary 2-phenylethylamines with high step- and atom-economy was reported. Notably, no substituent was required at the α-position to the amino group of the 2-phenylethylamines. The substrate scope was broad, and the reaction could also be applied to generate THIQs from the biologically active molecules such as the drug molecule baclofen and phenylalanine ester.
α-Diazo-β-ketonitriles: Uniquely reactive substrates for arene and alkene cyclopropanation
Nani, Roger R.,Reisman, Sarah E.
, p. 7304 - 7311 (2013/06/27)
An investigation of the intramolecular cyclopropanation reactions of α-diazo-β-ketonitriles is reported. These studies reveal that α-diazo-β-ketonitriles exhibit unique reactivity in their ability to undergo arene cyclopropanation reactions; other similar acceptor-acceptor- substituted diazo substrates instead produce mixtures of C-H insertion and dimerization products. α-Diazo-β-ketonitriles also undergo highly efficient intramolecular cyclopropanation of tri- and tetrasubstituted alkenes. In addition, the α-cyano-α-ketocyclopropane products are demonstrated to serve as substrates for SN2, SN2′, and aldehyde cycloaddition reactions.
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines
Neustadt, Bernard R.,Liu, Hong,Hao, Jinsong,Greenlee, William J.,Stamford, Andrew W.,Foster, Carolyn,Arik, Leyla,Lachowicz, Jean,Zhang, Hongtao,Bertorelli, Rosalia,Fredduzzi, Silva,Varty, Geoffrey,Cohen-Williams, Mary,Ng, Kwokei
scheme or table, p. 967 - 971 (2009/09/06)
Antagonism of the adenosine A2a receptor offers great promise in the treatment of Parkinson's disease. In the course of exploring pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonists, which led to clinical candidate SCH 420814, we prepared 1,2,4-triazolo[1,5-c]pyrimidines with potent and selective (vs A1) A2a antagonist activity, including oral activity in the rat haloperidol-induced catalepsy model. Structure-activity relationships and plasma levels are described for this series.
Structure-activity correlations for β-phenethylamines at human trace amine receptor 1
Lewin, Anita H.,Navarro, Hernan A.,Wayne Mascarella
, p. 7415 - 7423 (2008/12/22)
A cell line in which RD-HGA16 cells were stably transfected with the hTAAR 1 receptor was created and utilized to carry out a systematic evaluation of a series of β-phenethylamines. Fair agreement was observed with data obtained for aryl and ethylene chain substituted analogs in an AV12-664 cell line in which hemagglutinin-tagged hTAAR 1 was stably co-expressed with rat Gαs. Analogs with multiple substituents as well as analogs with bulky groups were found to be partial agonists. Analogs in which the primary amino group was converted to a secondary or a tertiary amino group by N-methylation were also partial agonists. Comparative Molecular Field Analysis (CoMFA) using the potency data yielded a regression coefficient r2 of 0.824. The steric field contribution to the model was 61% with the balance (39%) contributed by the electrostatic field. The collective results suggest that increasing steric bulk both at the amino nitrogen, particularly by N-dimethylation, and at the 4-position of the aromatic ring leads to low efficacy ligands.
Heterocyclic compound having oxime group
-
, (2010/02/14)
The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I) [where R1 and R2 independently represent a C1-6 alkyl group and the like that may have a hydrogen atom or a substituent; R3 represents a C1-6 alkyl group and the like that may have a substituent; R4 and R5 independent represents a hydrogen atom or a C1-6 alkyl group and the like that may have a substituent; R6 represents a hydrogen atom and the like; W represents —SO2— and the like; and X represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.
